Evidence map›Paper›PMID 30429226›Full record

ArticlemSphere2018

Nucleolar Relocalization of RBM14 by Influenza A Virus NS1 Protein.

Grant Beyleveld, Daniel J Chin, Elena Moreno Del Olmo, Jade Carter, Isabel Najera, Cristian Cillóniz, Megan L Shaw

Abstract read
In one paragraph

Article in mSphere, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Molecular signaling in coinfection: howFrontiers in immunology · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Grant BeyleveldDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Daniel J ChinRoche Pharma Research and Early Development, Immunology, Inflammation and Infectious Diseases Discovery and Translational Area, Roche Innovation Center, New York, New York, USA.
Elena Moreno Del OlmoDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Jade CarterRoche Pharma Research and Early Development, Immunology, Inflammation and Infectious Diseases Discovery and Translational Area, Roche Innovation Center, New York, New York, USA.
Isabel NajeraRoche Pharma Research and Early Development, Immunology, Inflammation and Infectious Diseases Discovery and Translational Area, Roche Innovation Center, New York, New York, USA.
Cristian CillónizRoche Pharma Research and Early Development, Immunology, Inflammation and Infectious Diseases Discovery and Translational Area, Roche Innovation Center, New York, New York, USA.
Megan L ShawDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA megan.shaw@mssm.edu.

Funding

SARS-CoV adaptations through a Systems Biology Lens (SYBIL)U19AI135972 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Adolfo Garcia-Sastre · 2018 to 2026
$27.2M
Spinning Disk Confocal MicroscopeS10RR024745 · NCRR · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FRIEDRICH, VICTOR LOUIS · 2009 to 2009
$500k
Host-targeted antivirals for influenza and other respiratory virus infectionsR21AI102169 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SHAW, MEGAN LOUISE · 2012 to 2013
$463k
NCRR NIH HHS S10 RR024745NIAID NIH HHS R21 AI102169NIAID NIH HHS U19 AI135972
6 · The paper itself

Abstract

Viruses utilize a number of host factors in order to carry out their replication cycles. Influenza A virus (IAV) and human respiratory syncytial virus (RSV) both infect the tissues of the respiratory tract, and as such we hypothesize that they might require similar host factors. Several published genome-wide screens have identified putative IAV host factors; however, there is significant discordance between their hits. In order to build on this work, we integrated a variety of "OMICS" data sources using two complementary network analyses, yielding 51 genes enriched for both IAV and RSV replication. We designed a targeted small interfering RNA (siRNA)-based assay to screen these genes against IAV under robust conditions and identified 13 genes supported by two IAV subtypes in both primary and transformed human lung cells. One of these hits, RNA binding motif 14 (RBM14), was validated as a required host factor and furthermore was shown to relocalize to the nucleolus upon IAV infection but not with other viruses. Additionally, the IAV NS1 protein is both necessary and sufficient for RBM14 relocalization, and relocalization also requires the double-stranded RNA (dsRNA) binding capacity of NS1. This work reports the discovery of a new host requirement for IAV replication and exposes a novel example of interplay between IAV NS1 and the host protein, RBM14.

Indexed as

Host-Pathogen InteractionsVirus ReplicationCell NucleolusCells, CulturedHumansInfluenza A virusIntracellular Signaling Peptides and ProteinsProtein TransportViral Nonstructural ProteinsINS1 protein, influenza virusIntracellular Signaling Peptides and ProteinsRBM14 protein, humanViral Nonstructural Proteinsinfluenza virusNS1 proteinRNA interferencesystems biologyvirus-host interactions

Identifiers

PMID30429226
PMCPMC6236804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.